Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
10 studies found for:    parp prostate cancer | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Studying the Effects of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Degarelix
2 Not yet recruiting Nivolumab in Prostate Cancer With Mutations in DNA Repair Defects (ImmunoProst Trial)
Condition: Prostate Cancer
Intervention: Drug: Nivolumab
3 Not yet recruiting Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Condition: Prostate
Intervention: Drug: Olaparib
4 Recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Castration-Resistant Prostate Carcinoma;   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
5 Recruiting A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Intervention: Drug: Rucaparib
6 Recruiting A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
7 Recruiting An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Condition: Prostatic Neoplasms
Intervention: Drug: Niraparib
8 Recruiting Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Conditions: Prostate Cancer Metastatic Castration-Resistant;   Abnormal DNA Repair;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Abiraterone Acetate;   Drug: Prednisone
9 Recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Conditions: Lung Cancer;   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Prostate Cancer;   Triple Negative Breast Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: MEDI4736
10 Recruiting A Study of SC10914 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: SC10914

Study has passed its completion date and status has not been verified in more than two years.